drugset / Trial / NCT06233292
A Study of ZG005 in Patients With Advanced Solid Tumors
RandomizedSequentialOpen-labelTreatment
Summary
This is a multi-center, open-label, Phase 1/2 study of ZG005 for the treatment of subjects with advanced solid tumors, and consists of three stages: dose escalation and confirmation of MTD/recommended dose.
Timeline
- Start
- 2022-06-17
- Primary completion
- 2026-01
- Completion
- 2026-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ZG005 | Unknown | 0.3 mg/kg | Intravenous |
| Subject | ZG005 | Unknown | 1 mg/kg | Intravenous |
| Subject | ZG005 | Unknown | 3 mg/kg | Intravenous |
| Subject | ZG005 | Unknown | 10 mg/kg | Intravenous |
| Subject | ZG005 | Unknown | 20 mg/kg | Intravenous |